In recent transactions involving OS Therapies Inc (NASDAQ:OSTX), a $42.7 million market cap biotech company, significant stock sales were reported by a major shareholder. Shalom Auerbach, acting through Einodmil LLC, sold 82,000 shares of common stock on May 7, 2025. The shares were sold at a weighted average price of $1.999, with the total transaction amounting to approximately $163,918. According to InvestingPro analysis, the stock is currently trading near its Fair Value, while analysts maintain a strong buy rating with price targets ranging from $6 to $20.
Post-transaction, Auerbach, who serves as the Principal of Einodmil LLC, holds indirect ownership of 2,664,199 shares. Additionally, direct ownership of 23,371 shares is reported. It’s important to note that Auerbach disclaims beneficial ownership of the shares held by Einodmil LLC, except to the extent of his pecuniary interest.
The shares were sold at prices ranging from $1.69 to $2.22 per share. Auerbach and Einodmil LLC have committed to providing detailed information about the number of shares sold at each price upon request.
In other recent news, OS Therapies has secured a key patent for its cancer immunotherapy platform, extending protection until 2040. This patent covers the company’s manufacturing methods and its pipeline, including the lead asset OST-HER2, which targets pediatric osteosarcoma. Additionally, the FDA has agreed to review a surrogate endpoint for OST-HER2, potentially leading to Breakthrough Therapy Designation and Accelerated Approval. The company anticipates submitting for FDA approval in early Q3 2025, with hopes for availability to patients by early 2026. OS Therapies has also acquired cancer immunotherapy assets from Ayala Pharmaceuticals, expanding its pipeline with candidates targeting over 30 cancer types. In shareholder news, OS Therapies received approval for a significant stock issuance, potentially exceeding 20% of its outstanding common stock. The company recently had to adjourn a Special Meeting of Stockholders due to a lack of quorum, rescheduling it for April 9, 2025. These developments highlight OS Therapies’ ongoing efforts to advance its position in the oncology field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.